Discussing AxSpA: Bimekizumab in AxSpA & Secukinumab Patient Clustering

The IMID Forum

Join us for the latest axSpA podcast brought to you by the CSF! This month Dr Sofia Ramiro, consultant rheumatologist and senior researcher at Leiden University Medical Centre and Zuyderland Medical Centre, is joined once again by experts with a wealth of clinical knowledge. Joining her is Hideto Kameda, Professor of Internal Medicine at Toho University as well as Atul Deodhar, Professor of Medicine and Medical Director of Rheumatology Clinics in the Division of Arthritis & Rheumatic Diseases at Oregon Health & Science University in Portland, USA. Also joining this insightful group is Xenofon Baraliakos, Professor of Internal Medicine and Rheumatology at the Ruhr-University in Bochum, and Medical Director of the rheumatology centre Rheumazentrum Ruhrgebiet in Herne, Germany In the first paper discussed, the authors compared the efficacy and safety of bimekizumab with biologic/targeted synthetic disease-modifying antirheumatic drugs in nr-axSpA and AS. Our second paper then goes on to identify distinct clinical clusters based on patient demographics and baseline clinical indicators from the clinical development programme of secukinumab in patients with a variety of rheumatological conditions.